Filed with ASX · · 3 pages · English
The focus of PainChek's US sales strategy is on assisted living and memory care, targeting a significant number of potential licenses. This expansion demonstrates PainChek's ability to convert its Master Services Agreement with Sabra into commercial contracts. The company aims to implement and activate licenses across these communities by the end of the year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
P: 1800 098 809 E: [email protected] W: painchek.com PainChek Limited (ASX: PCK) | PG 1 ABN 21 146 035 127 Suite 401, 35 Lime Street, Sydney, NSW, 2000, Australia ASX ANNOUNCEMENT 13 October 2026 PainChek expands Sabra contracts to 23 US communities US sales focus targets assisted living...
Follow PainChek into a list and get an email when it puts out news.
Follow PainChek